Voit lisätä twiitteihisi sijainnin, esimerkiksi kaupungin tai tarkemman paikan, verkosta ja kolmannen osapuolen sovellusten kautta. Halutessasi voit poistaa twiittisi sijaintihistorian myöhemmin. Lue lisää
Vaccine candidate was well tolerated at all doses with no serious adverse events reported within 28 days. Most adverse events were mild or moderate; 83% of those receiving low & middle doses & 75% in the high dose group reporting at least 1 adverse reaction within 7 days (2/3)pic.twitter.com/BxC93Yp5gj
Study of 108 adults finds vaccine produced neutralising antibodies and T-cell response against SARS-CoV-2, but further research is needed to confirm whether the vaccine protects against #SARSCoV2 infection (3/3)pic.twitter.com/Bwh0jZfnYb
"This report of an immunogenic, tolerable vaccine candidate is encouraging at the starting line for #COVID19 vaccine development."
NEW Linked Comment from N Lee & A McGeer on Zhu et al's study of a recombinant Ad5 vectored COVID-19 vaccine https://hubs.ly/H0qXVSW0 pic.twitter.com/wzokP4cD1F
They would already be well on their way with their own challenge trials.
Encouraging news. Thanks for sharing.
Encouraging and promising!
any big man can tell me， have it will be use in next mouth or two mouth？
一两个月？你想多了。这只是一期临床的结果啊。
The incidence of fever is concerning though this is probably from the vector.
17% grade 3 adverse-events in high-dose arm (largely fever);
although similar response d.14, 
at d.28 after high-dose
Thats a great news! Keep working
Twitter saattaa olla ruuhkautunut tai ongelma on muuten hetkellinen. Yritä uudelleen tai käy Twitterin tilasivulla saadaksesi lisätietoja.
